L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Rius Medical mission is to make its proprietary highly innovative platform available at year 2 to pharmaceutical and biotech partners - Proprietary cell lines for drug delivery. Engineer stem cells for next generation therapeutics as core business.
Waldachtal, Baden-Württemberg, Germany
Send a message
Next-Generation Consumer Experiences in my opinion is Health! Cancer and type 1 diabetes have clear “customer experience”/patient expectations in relation to therapeutics. Furthermore, this COVID-19 pandemic makes one thing clear, the rapid delivery of innovation.
 Cancer - Rapid delivery of innovation:
Next-Generation Consumer Experiences in cancer treatment implies “Next-Generation L-Asparaginase”! The drug L-Asparaginase, approved for medical use in 1978, is an expensive drug, but important in childhood acute lymphoblastic leukemia. PEGasparaginase (Half life 7 days) is preferred over native E. coli asparaginase (Half life 20 hours), because it is administered less frequently, with less daycare visits. Significantly longer is L-asparaginase encapsulation in erythrocytes for half-life 29 days (– blood donation derived, i.e. Erytech Pharma) and even stronger 120 days lifespan (– stem cells derived, i.e. Rius Medical). Encapsulated L-asparaginase implies, less frequently administration, requiring very fewer daycare-visits and is, therefore, more patient-friendly. In itself a convincing transformative positive effect on the long term to EU economy and society!
 Type 1 diabetes - Rapid delivery of innovation:
Next-Generation Consumer Experiences in type 1 diabetes treatment implies a cure! The flagship product of Rius Medical in re-inventing blood transfusion for antigen drug delivery is the cure to Autoimmune Disease type 1 diabetes among other autoimmune diseases like multiple sclerosis (MS) and Celiac Disease in relation to Switzerland, Lausanne Anokion partnership with Japan Astellas Pharma and with USA Bristol Myers Squibb. Rius Medical sees an opportunity to play a stronger role in the industry by focusing on Advanced Manufacturing – by supplying the industry with innovation! Rius Medical vision of a radically new technology is Advanced Manufacturing for tackling current bottlenecks from discovery to the manufacturing step of clinical grade medicinal products. Rius Medical is making use of advanced manufacturing that integrates new innovative technologies in both products and processes – as B2B solutions!
ONE Platform technology that does the above is best understood as “Microsoft Windows by Bill Gates”! That’s right, Rius Medical is indeed applying the “biotechnology equivalent” of Microsoft Windows to stem cells in having a new "gene technology" operating system for red blood cells / proprietary cell lines for drug delivery. So doing in Rius Medical, you will find a founder and a team arranged as a consortium with the potential to shape the industry we are all part of, the Health industry - much like personal computers shape modern society since 1990s. A potential investor brought me to that observation and others can expect transparent communication from my side.
Red biotechnology it is and as a provider of B2B solutions, Rius Medical emphasises on providing innovation - tools that help businesses (e.g. Erytech Pharma, Anokion among others) to produce better services for consumers. Are you against learning about the bold ideas of Rius Medical in a 20mins Zoom call? Email me for a day this week or next, to your convenience?
PS: As bridge financing Rius Medical seeks EUR 400,000 for project start as of July 2021 instead of December 2021. A bridge financing as Rius Medical awaits European Commission’s EIC Pathfinder OPEN grant of EUR 2.5 million.
Many thanks and warmest regards,
Founder and CEO
Biotech in Europe: A strong foundation for growth and innovation
Switzerland’s Anokion and Orphan Technologies both acquired to USA is proof of Europe biotech contribution to innovation. For investors seeking the most out of innovation in biotech, Advanced manufacturing has the following characteristics: (1) huge end markets; (2) big problems solvable through technology; (3) some level of regulatory or standards know-how; and (4) positive impact on the world.
The greatest scientific problems of the day for cell and gene therapy is industrial challenges related to the logistic of manufacturing and Cost of Goods in bringing these cellular therapies from the clinic to commercial implementation. Advanced manufacturing is the use of innovative technology to improve products and processes, with the relevant technology being described as "advanced," "innovative," or "cutting edge".
Rius Medical develops a proprietary, flexible manufacturing platform that automates and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The mission of the Rius Medical platform is to fully automate cell and gene therapy (CGT) manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of life-saving treatments.
Rius Medical is one European company that sees an opportunity to play a stronger role in the industry by focusing on Advanced Manufacturing. So doing by supplying the industry with innovation!
[Do not miss the Industry update by Rius Medical – available on LinkedIN Rius Medical www]
Rius Medical – Innovative Science and Technology are at the Heart of Everything we do!
For the few investors seeking life sciences venture in early-stage companies, this announcement bring fourth innovative new ideas where Artificial Intelligence combine with innovative biotech technologies speed up development process of therapeutics to address the current and future Coronavirus outbreaks.
[Reuters, July 2020] Six months into a global COVID-19 pandemic that has infected more than 12 million people, questions remain about whether the antibody response to this virus is robust and lasts over time www. As scientists question whether the presence, or absence, of antibodies to the novel Coronavirus can reliably determine immunity, some are looking to a different component of the immune system, known as T cells, for their role in protecting people in the pandemic.
[Blog, July 2020] Dr. Francis Collins, Director of the United States National Institutes of Health (NIH) commented the following: Much of the study on the immune response to SARS-CoV-2, the novel Coronavirus that causes COVID-19, has focused on the production of antibodies. But, in fact, immune cells known as memory T cells also play an important role in the ability of our immune systems to protect us against many viral infections, including – it now appears – COVID-19 www. What’s clear from this study “by Bertoletti’s team” is our past experiences with Coronavirus infections may have something important to tell us about COVID-19.
Artificial Intelligence comes to the rescue in taming the Coronavirus literature www. AI and biomedical Developers are a great union. The COVID-19 literature has grown in much the same way as the disease’s transmission: exponentially. Artificial Intelligence refers to a broader idea where machines can execute tasks "smartly". Artificial Intelligence (AI) applies machine learning, deep learning and other techniques to solve actual problems. Deep learning is an artificial intelligence function that imitates the workings of the human brain in processing data and creating patterns for use in decision-making. The goal is to provide an even more powerful environment for mining COVID-19 literature that lists more than 28,000 articles — far too many for any researcher/scientist to read.
Investors seeking technologies to improve lives and generate returns, here with Rius Medical, are welcome to inquirer on Rius Medical’s cutting-edge technology that also enlist Artificial Intelligence to improve lives and generate returns! Your investment in Rius Medical “Scale up” manufacturing processes for multiple products also enables the development of therapeutics to address the current and future Coronavirus outbreaks.
Are you against a brief 3 minutes talk to learn more?
Many thanks and warmest regards,
Founder and CEO
Rius Medical based in Germany has a technology to upgrade French base company Erytech Pharma using red blood cells for drug delivery of therapeutic protein L-Asparaginase, thus targeting multiple cancers.
To the disappointment of Recordati an investor to Erytech Pharma, Erytech Pharma discontinued it’s Leukaemia program in June 2018 despite successful phase III clinical data with Acute Lymphoblastic Leukemia (ALL) and instead shifted focus to solid tumor, now under phase III clinical studies. Cell & Gene Therapy will shape the future of medicine, when novel technologies proceed beyond the primary goals of safety and efficacy. Uneconomical manufacturing is an industry challenge and represents a major roadblock to the sustainable commercialisation of cellular products. The solution, Rius Medical technology engineers stem cells into therapeutic products and provides a Business-to-Business solution to France-based Erytech Pharma for upgraded red blood cells that do more than simply carry oxygen.
Furthermore, from the perspective of French pharmaceutical company Servier Laboratories, seeking opportunities in FIVE areas of research and development being cardiovascular diseases, cancer, diabetes, neuropsychiatric diseases like multiple sclerosis and immune-inflammatory diseases; Rius Medical platform technology for the delivery of therapeutic protein encapsulated in red blood cells addresses all FIVE of them. The upgrade there is with antigen-loaded red blood cells against Autoimmune diseases.
As a young company not doing incremental improvements, Rius Medical develops a platform technology to engineer stem cells for next generation therapeutics as core business. Rius Medical mission is to make its highly innovative platform technology available at 3 years to pharmaceutical and biotech partners. In addressing Ageing and Ageing-related diseases such as cardiovascular disease, Rius Medical is a Deep tech company bringing innovation to an aging society with Deep Tech for healthcare.
This is the path of Rius Medical making the French economy more competitive by boosting French companies Erytech Pharma and Servier Laboratories in bringing their products to market following an upgrade in technology. For the French economy, that translates into local Job creation and a healthier work force within an ageing population.
Denis Demarais (BSc)
Founder, CEO and Chief Scientific Officer
Start in 31 August 2016
31 August 2016
registration with the commercial register of Stuttgart local court under folio HRB 757947
to be continued ...